Skip to main content

Table 4 Organisations and individuals noted by respondents as having an important influence on changing policies related to the use of magnesium sulphate in their countries (%)

From: Translating research into policy and practice in developing countries: a case study of magnesium sulphate for pre-eclampsia

Organisation or individuals Low and lower-middle income countries
(n = 39#)
Upper-middle income countries
(n = 20#)
High-income countries
(n = 24#)
Medical or obstetrical association 92% 85% 88%
Hospital department of obstetrics 87% 85% 83%
Central health authorities 82% 70% 38%
Hospital administration 79% 60% 17%
World Health Organisation 79% 45% 8%
Nurse or midwife association 72% 35% 58%
Drug licensing agency 72% 10% 46%
Pharmaceutical industry 69% 25% 33%
Regional or local health authorities 67% 90% 33%
Mass media 56% 20% 46%
Individual influential professionals 51% 55% 75%
Politicians 51% 55% 8%
Public health insurance program 26% 65% 13%
Private health insurers 26% 35% 8%
Non-governmental organisations 26% 15% 4%
Other international organisations 26% 15% 4%
Other professional associations 21% 15% 17%
Patient organisations 13% 10% 33%
Others 13% 25% 21%
  1. # Number of respondents.